GLP-1 & Incretin Science

The Estimand That Made Placebo Look Better

UKPWritten and published by UK Peptides4 min readUpdated 2 cited sources

The short answer

Switching from the efficacy estimand to the treatment-regimen estimand usually shrinks a drug's measured effect. In TRIUMPH-4 it shrank both active arms as expected but more than doubled the placebo arm's weight loss, narrowing the gap from both ends at once.

Key facts

Trial
TRIUMPH-4 (NCT05931367)
Placebo, efficacy estimand
-2.1% (-2.1 kg)
Placebo, treatment-regimen estimand
-4.6% (-5.3 kg)
Higher dose, efficacy estimand
-28.7%
Higher dose, treatment-regimen estimand
-23.7%
Gap, efficacy estimand
26.6 percentage points
Gap, treatment-regimen estimand
19.1 percentage points
Trial duration
68 weeks

What an estimand is, briefly

An estimand is a precise statement of what a trial is estimating, including how it handles events that occur after randomisation (stopping treatment, starting something else, having surgery). Two analyses of the same data can produce different numbers not because one is wrong but because they answer different questions. The efficacy estimand asks what would happen if participants remained on randomised treatment without rescue. The treatment-regimen or treatment-policy estimand asks what happened, counting all data regardless of what participants did afterwards.

The usual direction, and the exception

Normally the treatment-regimen estimand gives a smaller effect, because it includes data from people who stopped the drug and regained weight. TRIUMPH-4's active arms behave exactly that way: -26.4% becomes -20.0%, and -28.7% becomes -23.7%. The placebo arm goes the other way. Its weight change moves from -2.1% under the efficacy estimand to -4.6% under the treatment-regimen estimand, more than doubling. A placebo arm that loses more weight when everything that happened is counted needs explaining.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

The most likely explanation

The arithmetic is unambiguous; the explanation is inferential, and the sponsor's topline does not spell it out. The reading that fits is that participants who left the placebo arm did not simply resume their previous trajectory. Some of them obtained effective weight-loss treatment outside the trial. Under the efficacy estimand those post-discontinuation observations are excluded or handled as if treatment had continued; under the treatment-regimen estimand they are counted as they occurred. The placebo arm therefore becomes, in part, a treated arm, and its measured weight loss rises. Other contributors are possible: differential dropout, intercurrent illness, or lifestyle intervention effects concentrated among those who left. None of these can be separated from the published topline.

Why it narrows the gap from both ends

This is the part that matters for interpretation. The drug arms shrink because discontinuers regain; the placebo arm grows because discontinuers get treated elsewhere. The measured difference between them falls twice as fast as either movement alone. At the higher dose the gap goes from 26.6 percentage points on the efficacy estimand to 19.1 on the treatment-regimen estimand. That is a 28% reduction in the estimated treatment difference driven entirely by the analytical question asked, not by anything that happened in the joints or the gut of any participant.

Why this gets worse every year

A placebo arm in an obesity trial is only a placebo arm if it stays untreated. That was easier to arrange when there was little effective treatment to leave for. It is now much harder: participants randomised to placebo in a 68-week trial have licensed, effective options available, and there is no ethical mechanism to prevent them from seeking those options. As effective agents spread, placebo arms in this field will drift further toward being partially treated arms, and treatment-policy estimands will drift further from efficacy estimands. This is a structural problem for the field's evidence base, not a flaw in any one trial.

What to do with this when reading a result

Three things. Check which estimand a quoted number comes from, because the same trial routinely publishes both. Never compare a number from one estimand against a number from another, even within the same trial. And when a placebo arm shows unexpected movement, treat it as information about the trial's conduct rather than as background noise. It is often the most revealing number in the table.

Quick reference

ArmEfficacy estimandTreatment-regimen estimandDirection
Retatrutide 9 mg-26.4%-20.0%Effect shrinks
Retatrutide 12 mg-28.7%-23.7%Effect shrinks
Placebo-2.1%-4.6%Loss more than doubles
Gap at higher dose26.6 points19.1 pointsNarrows 28%

Frequently asked questions

Is one estimand more honest than the other?

No. They answer different questions and regulators generally want both. The efficacy estimand describes the drug's pharmacological effect under ideal adherence; the treatment-regimen estimand describes what a population randomised to that strategy actually experienced. Neither is the truth on its own.

Does this mean published weight-loss figures are inflated?

It means the headline figure is usually the efficacy estimand, which is the larger of the two and describes conditions that do not obtain outside a trial. That is not inflation, but it is a systematic reason real-world results come in lower (the same reason covered in the efficacy-effectiveness gap).

Could the placebo arm result be a data error?

It is an unusual pattern but not an implausible one, and it is exactly what post-randomisation treatment in a control arm produces. The full publication would be expected to describe intercurrent events by arm, which is where the explanation would be confirmed or replaced.

Does this affect other obesity trials?

Increasingly, yes. Any long placebo-controlled obesity trial running while effective treatments are widely available faces the same pressure. Check control-arm weight change in any trial you read; a control arm losing several percent of body weight is telling you something about what happened outside the protocol.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.